JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 19.02 Billion KRW | -59.07% |
| 2022 | 46.48 Billion KRW | 948.16% |
| 2021 | 4.43 Billion KRW | 31.0% |
| 2020 | 3.38 Billion KRW | 110.7% |
| 2019 | -31.63 Billion KRW | -236.55% |
| 2018 | 23.16 Billion KRW | -57.11% |
| 2017 | 54.02 Billion KRW | 723.56% |
| 2016 | -8.66 Billion KRW | -4875.56% |
| 2015 | 181.41 Million KRW | 102.02% |
| 2014 | -8.98 Billion KRW | -150.44% |
| 2013 | 17.81 Billion KRW | 180.87% |
| 2012 | -22.03 Billion KRW | 31.39% |
| 2011 | -32.11 Billion KRW | -177.72% |
| 2010 | -11.56 Billion KRW | -1210.99% |
| 2009 | 1.04 Billion KRW | 120.15% |
| 2008 | -5.16 Billion KRW | 28.58% |
| 2007 | -7.23 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 29.75 Billion KRW | 139.68% |
| 2024 Q1 | 12.41 Billion KRW | -4.77% |
| 2023 Q1 | 30.44 Billion KRW | 118.77% |
| 2023 Q3 | 2.42 Billion KRW | 117.97% |
| 2023 FY | 19.02 Billion KRW | -59.07% |
| 2023 Q4 | 13.03 Billion KRW | 437.86% |
| 2023 Q2 | -13.49 Billion KRW | -144.32% |
| 2022 Q4 | 13.91 Billion KRW | -10.59% |
| 2022 Q2 | 1.87 Billion KRW | -87.57% |
| 2022 FY | 46.48 Billion KRW | 948.16% |
| 2022 Q1 | 15.12 Billion KRW | 238.78% |
| 2022 Q3 | 15.56 Billion KRW | 728.0% |
| 2021 Q4 | -10.89 Billion KRW | -351.47% |
| 2021 FY | 4.43 Billion KRW | 31.0% |
| 2021 Q1 | 6.03 Billion KRW | -53.7% |
| 2021 Q2 | -2.25 Billion KRW | -137.32% |
| 2021 Q3 | 4.33 Billion KRW | 292.23% |
| 2020 Q2 | -2.18 Billion KRW | 9.81% |
| 2020 Q1 | -2.42 Billion KRW | 90.4% |
| 2020 FY | 3.38 Billion KRW | 110.7% |
| 2020 Q4 | 13.04 Billion KRW | 1972.6% |
| 2020 Q3 | 629.37 Million KRW | 128.79% |
| 2019 Q4 | -25.23 Billion KRW | -1774.46% |
| 2019 Q3 | 1.5 Billion KRW | 219.15% |
| 2019 Q2 | -1.26 Billion KRW | 85.02% |
| 2019 Q1 | -8.44 Billion KRW | 12.83% |
| 2019 FY | -31.63 Billion KRW | -236.55% |
| 2018 Q4 | -9.68 Billion KRW | 42.74% |
| 2018 Q1 | -1.69 Billion KRW | 80.61% |
| 2018 FY | 23.16 Billion KRW | -57.11% |
| 2018 Q2 | 51.77 Billion KRW | 3148.81% |
| 2018 Q3 | -16.91 Billion KRW | -132.68% |
| 2017 Q3 | -1.36 Billion KRW | -136.93% |
| 2017 FY | 54.02 Billion KRW | 723.56% |
| 2017 Q4 | -8.75 Billion KRW | -539.94% |
| 2017 Q1 | -2.12 Billion KRW | 60.93% |
| 2017 Q2 | 3.7 Billion KRW | 274.11% |
| 2016 Q1 | 630.89 Million KRW | 251.19% |
| 2016 Q2 | -6.61 Billion KRW | -1148.73% |
| 2016 Q3 | 3.78 Billion KRW | 157.23% |
| 2016 FY | -8.66 Billion KRW | -4875.56% |
| 2016 Q4 | -5.44 Billion KRW | -243.87% |
| 2015 FY | 181.41 Million KRW | 102.02% |
| 2015 Q4 | 179.64 Million KRW | 154.37% |
| 2015 Q2 | 1.07 Billion KRW | 244.77% |
| 2015 Q1 | -742.04 Million KRW | 31.7% |
| 2015 Q3 | -330.42 Million KRW | -130.76% |
| 2014 Q3 | -41.05 Million KRW | 98.76% |
| 2014 Q2 | -3.3 Billion KRW | 27.63% |
| 2014 Q1 | -4.56 Billion KRW | -130.1% |
| 2014 FY | -8.98 Billion KRW | -150.44% |
| 2014 Q4 | -1.08 Billion KRW | -2546.0% |
| 2013 Q1 | -3.55 Billion KRW | 69.14% |
| 2013 Q3 | -4.75 Billion KRW | -116.93% |
| 2013 Q4 | -1.98 Billion KRW | 58.35% |
| 2013 FY | 17.81 Billion KRW | 180.87% |
| 2013 Q2 | 28.09 Billion KRW | 890.06% |
| 2012 Q4 | -11.52 Billion KRW | -142.47% |
| 2012 Q2 | -1.83 Billion KRW | 58.02% |
| 2012 Q1 | -4.37 Billion KRW | 0.0% |
| 2012 FY | -22.03 Billion KRW | 31.39% |
| 2012 Q3 | -4.75 Billion KRW | -158.53% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | -32.11 Billion KRW | -177.72% |
| 2011 Q2 | -2.37 Billion KRW | -144.21% |
| 2011 Q1 | 5.37 Billion KRW | 0.0% |
| 2011 Q3 | -1.45 Billion KRW | 38.74% |
| 2010 Q3 | -706.19 Million KRW | -251.11% |
| 2010 Q4 | - KRW | 100.0% |
| 2010 FY | -11.56 Billion KRW | -1210.99% |
| 2010 Q2 | 467.33 Million KRW | -59.67% |
| 2010 Q1 | 1.15 Billion KRW | 0.0% |
| 2009 FY | 1.04 Billion KRW | 120.15% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 2.26 Billion KRW | 125.42% |
| 2009 Q2 | 1 Billion KRW | 120.37% |
| 2009 Q1 | 455.89 Million KRW | 0.0% |
| 2008 FY | -5.16 Billion KRW | 28.58% |
| 2008 Q4 | - KRW | 100.0% |
| 2008 Q2 | 2.88 Billion KRW | 204.27% |
| 2008 Q3 | -1 Billion KRW | -134.75% |
| 2008 Q1 | -2.76 Billion KRW | 0.0% |
| 2007 FY | -7.23 Billion KRW | 0.0% |
| 2007 Q3 | -3.62 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | 100.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 364.957% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 67.19% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 131.93% |
| HANDOK Inc. | -28.79 Billion KRW | 166.069% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 326.095% |
| Yuhan Corporation | 93.5 Billion KRW | 79.653% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -71.062% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 176.682% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 86.989% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -442.274% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 859.104% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1017.411% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 520.485% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 14.806% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 364.957% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 190.857% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -430.96% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 116.087% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 124.106% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 91.047% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.586% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 133.19% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -210.798% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1043.723% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -280.165% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 364.957% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 48.53% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 82.936% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.586% |
| Yuhan Corporation | 93.5 Billion KRW | 79.653% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 217.087% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 590.932% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -210.926% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.586% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -0.637% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 60.577% |
| CKD Bio Corp. | -24.19 Billion KRW | 178.645% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 20.448% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 30.658% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 36.098% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 133.19% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 59.525% |
| Boryung Corporation | 40.2 Billion KRW | 52.674% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 160.729% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 859.104% |
| JW Lifescience Corporation | 28.14 Billion KRW | 32.397% |